MiNK Therapeutics (INKT)
NASDAQ:INKT
US Market
Holding INKT?
Track your performance easily

MiNK Therapeutics (INKT) Income Statement

115 Followers

MiNK Therapeutics Income Statement

Last quarter (Q2 2024), MiNK Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, MiNK Therapeutics's net income was $-2.70M. See MiNK Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 689.63K
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 17.46M$ 22.92M$ 30.95M$ 28.36M$ 10.80M$ 23.48M
Operating Income
$ -17.62M$ -22.92M$ -30.95M$ -28.36M$ -10.80M$ -22.79M
Net Non Operating Interest Income Expense
$ 203.79K$ 463.26K$ 253.32K$ -2.43M$ -2.44M$ -1.56M
Other Income Expense
$ -330.93K$ -10.00$ 2.70M$ -577.43K$ -3.00M$ 551.24K
Pretax Income
$ -16.92M$ -22.46M$ -27.99M$ -30.21M$ -16.24M$ -23.80M
Tax Provision
$ -1.69M$ -1.69M$ -104.00K$ -511.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -17.09M$ -22.46M$ -27.99M$ -30.21M$ -16.24M$ -23.80M
Basic EPS
$ -0.48$ -0.65$ -0.83-$ -0.60$ -0.93
Diluted EPS
$ -0.48$ -0.65$ -0.83$ -1.16$ -0.60$ -0.93
Basic Average Shares
$ 140.85M$ 34.36M$ 33.67M$ 26.03M$ 26.95M$ 25.55M
Diluted Average Shares
$ 140.85M$ 34.36M$ 33.67M$ 26.03M$ 26.95M$ 25.55M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 17.46M$ 22.92M$ 30.95M$ 28.36M$ 10.80M$ 23.48M
Net Income From Continuing And Discontinued Operation
$ -17.09M$ -22.46M$ -27.99M$ -30.21M$ -16.24M$ -23.80M
Normalized Income
$ -13.70M$ -24.15M--$ -16.24M$ -23.80M
Interest Expense
----$ 2.44M$ 1.56M
EBIT
$ -17.29M$ -22.92M$ -30.95M$ -27.78M$ -13.80M$ -22.24M
EBITDA
$ -17.09M$ -22.72M$ -30.83M$ -27.70M$ -13.74M$ -22.20M
Currency in USD

MiNK Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis